Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CRYSTODIGIN vs CEDILANID-D
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.
Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.
Treatment of heart failure with reduced ejection fraction (FDA-approved),Control of ventricular response in atrial fibrillation and atrial flutter (FDA-approved)
Heart failure,Atrial fibrillation,Atrial flutter
0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.
0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.
Terminal elimination half-life approximately 1.6–1.9 days (38–45 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 36-48 hours in patients with normal renal function; prolonged to >100 hours in severe renal impairment, requiring dose adjustment.
Primarily renal excretion; minimal hepatic metabolism. Not significantly metabolized by cytochrome P450 enzymes.
Hepatic (minor); primarily renally excreted unchanged.
Primarily renal excretion of unchanged drug; ~80-90% eliminated in urine, ~10-20% in feces via biliary excretion.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 30-40%, with enterohepatic circulation present.
~20–25% bound to plasma proteins, primarily albumin.
25-30% bound to plasma albumin.
Vd approximately 5–10 L/kg, indicating extensive tissue distribution; clinical significance: large Vd means low plasma concentration relative to total body load, necessitating loading doses.
6-10 L/kg; large Vd indicates extensive tissue distribution and high cardiac tissue affinity.
Oral: 60–80% (variable, depends on formulation and gastrointestinal factors); Intravenous: 100%.
Oral: 70-80%; IV: 100%.
Cr Cl 10-50 m L/min: reduce dose by 25-50%; Cr Cl <10 m L/min: reduce dose by 50-75% or use alternative.
GFR <50 m L/min: reduce dose by 50% or extend dosing interval to every 36-48 hours. GFR <10 m L/min: avoid use or reduce dose by 75%.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Loading dose: 10-20 mcg/kg intravenously over 2-4 hours; maintenance: 5-10 mcg/kg every 6 hours as needed.
Digitalizing dose: 0.01-0.02 mg/kg IV or IM, given in divided doses over 24 hours. Maintenance: 10-20% of digitalizing dose daily. Not recommended for neonates due to prolonged half-life.
Start at lower end of dosing range (0.25 mg intravenously), adjust based on renal function and response, monitor for toxicity.
Reduce dose by 25-50% due to decreased renal function and increased sensitivity. Monitor serum levels and renal function closely.
None.
Can cause potentially fatal arrhythmias; use only when clearly indicated and monitor serum levels.
Narrow therapeutic index; toxicity can be life-threatening.,Hypokalemia, hypomagnesemia, and hypercalcemia increase risk of digoxin toxicity.,Electrolyte monitoring and dose adjustment in renal impairment.,Patients with acute myocardial infarction, myocarditis, or severe pulmonary disease may be at increased risk of arrhythmias.
Narrow therapeutic index; toxicity risk increased with hypokalemia, hypomagnesemia, hypercalcemia, renal impairment; monitor ECG and drug levels.
Ventricular fibrillation,Known hypersensitivity to digoxin or other digitalis glycosides,Hypercalcemia,Hypokalemia (uncorrected),Atrioventricular block (second- or third-degree) unless a pacemaker is present,Hypertrophic obstructive cardiomyopathy (relative contraindication)
Ventricular fibrillation, digitalis toxicity, hypersensitivity, AV block (unless pacemaker present), Wolff-Parkinson-White syndrome.
Avoid high-fiber foods and large amounts of bran or pectin, as they may reduce absorption. Grapefruit juice may increase blood levels; limit consumption. Consistent dietary potassium intake is important; extremes (high or low) can affect drug action.
Avoid licorice, which can cause hypokalemia. Maintain consistent intake of potassium-rich foods (bananas, oranges) to avoid fluctuations. No known significant food interactions beyond electrolyte effects.
Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fetal bradycardia and hypoxia due to placental transfer. Third trimester: Risk of neonatal digitalis toxicity, including arrhythmias and heart block.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avoids if possible.
Excreted in breast milk in low concentrations (M/P ratio approximately 0.75-1.0). Considered compatible with breastfeeding; monitor infant for signs of toxicity (bradycardia, vomiting).
Deslanoside is excreted in breast milk; estimated infant dose 0.1-0.5% of maternal weight-adjusted dose; M/P ratio not well defined. Monitor infant for bradycardia, feeding difficulties; benefit likely outweighs risk.
Increased volume of distribution and renal clearance in second and third trimesters may necessitate dose increases. Monitor serum digoxin levels and adjust to maintain therapeutic range (0.5-1.0 ng/m L).
Increased renal clearance in pregnancy may require higher doses; monitor serum drug levels and adjust accordingly. Reduced dosing in third trimester may be needed due to volume expansion.
Crystodigin (digitoxin) has a very long half-life (~5-7 days) requiring careful monitoring to avoid accumulation. Unlike digoxin, it is primarily hepatically metabolized, so renal impairment has less impact on dosing. Always check for drug interactions with CYP3A4 inducers/inhibitors. Therapeutic monitoring of serum levels is essential (target 15-25 ng/m L).
Cedilanid-D (deslanoside) is a rapidly acting parenteral digitalis glycoside. Use with extreme caution in renal impairment due to reduced clearance. Monitor serum potassium and magnesium; hypokalemia and hypomagnesemia potentiate toxicity. Administer slow IV push over 5 minutes to avoid arrhythmias. Therapeutic drug monitoring less common due to short half-life of 33 hours. Contraindicated in ventricular tachycardia and AV block (unless due to atrial fibrillation).
Take exactly as prescribed; do not miss doses or double up.,Report any symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), or irregular heartbeat.,Avoid over-the-counter medications without consulting your doctor, especially antacids and laxatives.,Keep regular appointments for blood tests to monitor drug levels and kidney function.,Do not stop suddenly; withdrawal can worsen heart condition.
Take exactly as prescribed; do not double doses.,Report symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), irregular heartbeat.,Avoid over-the-counter medications without consulting doctor.,Maintain consistent potassium intake; avoid high-potassium foods or supplements unless advised.,Monitor daily weight and report rapid weight gain or edema.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CRYSTODIGIN vs CEDILANID-D, answered by our medical review team.
CRYSTODIGIN is a Cardiac Glycoside that works by Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.. CEDILANID-D is a Cardiac Glycoside that works by Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CRYSTODIGIN and CEDILANID-D depend on the specific clinical indication. These are both Cardiac Glycoside agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CRYSTODIGIN is: 0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.. The standard adult dose of CEDILANID-D is: 0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CRYSTODIGIN and CEDILANID-D in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CRYSTODIGIN is classified as Category C. Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fe. CEDILANID-D is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.